#Tecartus

Cancerpatientpower.info

Barriers to CAR T-Cell Therapy: Cost and Clinical Effectiveness

What Is the Cost and Clinical Effectiveness of CAR T-Cell Therapy?. Use of cellular immunotherapies such as chimeric antigen receptor (CAR) T-cell therapy remains limited, partly due to barriers in cost and clinical effectiveness, said Jeffrey A. Tice, MD, of the University of California, San Francisco (UCSF), in a virtual presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
Picture for Barriers to CAR T-Cell Therapy: Cost and Clinical Effectiveness
Cancerajmc.com

Studies Offer Promising Data on CAR T-cell Therapy in B-ALL, Multiple Myeloma

Two abstracts presented recently at the American Society of Clinical Oncology annual meeting offered promising data for 2 CAR T-cell therapies, one in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and one in R/R multiple myeloma. Abstracted presented recently at the American Society of Clinical Oncology annual meeting offered promising data...
Picture for Studies Offer Promising Data on CAR T-cell Therapy in B-ALL, Multiple Myeloma
TRENDING TOPICS
Canceraacrjournals.org

In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL

Combining synthetic biology with adoptive T-cell transfer has led to promising advances in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), diffuse large B-cell lymphoma (DLBCL), and mantle cell lymphoma (MCL). Chimeric antigen receptors (CARs) are synthetic receptors that redirect T-cell specificity against cancer. CARs include “built-in” signaling domains that reprogram T-cell metabolism, enhance effector function, and support long-term persistence. Despite their success in blood-based malignancies, relapse can occur in CD19-redirected CAR T-cell therapies for several reasons, including poor engraftment, impaired in vivo proliferation, and T-cell senescence. Herein, we explain how subtle alterations in CAR design may overcome barriers to effective adoptive immunotherapy. We also discuss how the physiochemical properties of the single-chain variable fragment (scFv) affect differentiation and persistence. Moreover, we describe innovative advances in CAR engineering and provide insight into the development of humanized scFvs whose proposed benefits include increased persistence and improved clinical outcomes. Tumor cells can evade CAR T-cell–mediated detection and elimination due to the emergence or presence of CD19-negative leukemic cell subpopulations. We also discuss the opportunities and challenges in targeting other B-ALL–associated antigens. Identifying alternate targets is fundamentally necessary to restore the success of CAR T-cell therapies in CD19-negative patients with B-ALL.
Cancermetroatlantaceo.com

Northside Launches New Program for Head and Neck Cancers

The U.S. Food and Drug Administration (FDA) has approved ABECMA® (idecabtagene vicleucel; ide-cel), from Bristol Myers Squibb and bluebird bio, Inc. ABECMA is the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
YOU MAY ALSO LIKE